Navigation Links
Abaxis Announces Management Transition
Date:9/20/2013

UNION CITY, Calif., Sept. 20, 2013 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood instrumentation and consumables to the medical, research and veterinary markets, announced today that Martin Mulroy has resigned his position as the Company's chief commercial officer effective October 4, 2013 to pursue other business and personal interests. In the interim, Don Wood, Chief Operations Officer, will temporarily assume the responsibilities for leading Abaxis' North American Animal Health (NAAH) business as the Company executes a national search to appoint a successor. The search will encompass both internal and external candidates.

Clint Severson, chairman and chief executive officer of Abaxis, said, "I want to express my appreciation to Marty for his dedication and contributions in growing our veterinary business over the past 15 years. Marty built a successful platform in the veterinary business that will insure our continuing success for many years. A broad national search will commence immediately to hire a leader that can leverage that platform for the benefit of the Company and, in turn, enhance shareholder value. I, along with the entire Abaxis team, wish Marty the best in his future endeavors."

About Abaxis
Abaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer. The veterinary business also provides to the animal health and research market a line of hematology instruments for point-of-care complete blood counts (CBC), a specialty instrument to screen for and detect clotting disorders and to measure equine fibrinogen levels, a handheld instrument for the rapid assessment of certain critical care tests and rapid point-of-care tests for Heartworm infections in dogs, Parvovirus, Lyme and Giardia.  Abaxis, through its AVRL Division, provides routine laboratory testing as well as specialty testing for veterinarians nationwide. This state-of-the-art commercial laboratory will be the hub of the Abaxis Veterinary Reference Laboratories (AVRL).
For more information, visit http://www.abaxis.com.

Forward Looking Statements
This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations.  Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act.  These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts.  Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to risks related to transitioning our medical sales to Abbott, losses or system failures with respect to Abaxis' facilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products and services, the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy.  Readers should also refer to the section entitled "Risk Factors" in Abaxis' annual report on Form 10-K, recent quarterly reports on Form 10-Q and Abaxis' other periodic reports filed with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.Contact:

Abaxis, Inc.

Lytham Partners, LLCClint Severson

Joe Dorame, Robert Blum and Joe DiazChief Executive Officer

602-889-9700510-675-6500
'/>"/>

SOURCE Abaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Abaxis, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
2. Abaxis Enters Into Definitive Agreement To Deliver 300 Piccolo Xpress Instruments For A Four-Year Drug Clinical Trial
3. Abaxis To Report First Quarter Fiscal Year 2013 Financial Results Thursday, July 26, 2012
4. Abaxis Reports Financial Performance For The First Quarter Of Fiscal 2013
5. Abaxis, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
6. Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference
7. Abaxis, Inc. to Present at CL Kings 10th Annual Best Ideas Conference 2012
8. Abaxis, Inc. to Present at UBS Global Life Sciences Conference
9. Abaxis Announces the Launch of Kidney Profile Plus Panel
10. Abaxis Announces Exclusive Distribution Agreement with Abbott
11. Abaxis, Inc. to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 The National ... health and data analytics company, signed a Memorandum ... improving healthcare delivery in the region. ... Global Health Research and Technology (BIGHEART) at NUS ... several topics related to healthcare IT and medical ...
(Date:3/27/2017)...  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, ... and efficacy studies. The company is harnessing the power ... MAGE A, in an effort to find a better ... After 4 weeks of treatment in transgenic mice, the ... in a full toxicology report of various organs. Cytotoxic ...
(Date:3/27/2017)... 27, 2017  Sanderling Ventures, portfolio company, Torax ... division of Johnson & Johnson. Torax manufactures and markets ... of gastro-esophageal reflux disease (GERD). The LINK device ... and the procedure is currently available in the ... Medical was founded by Sanderling Ventures, Mayo Medical ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 28, 2017 , ... Qualidigm , the mission-driven national ... a new, more expansive office space in order to accommodate its growing number ... office building in Wethersfield, Conn. located at 936 Silas Deane Highway and immediately ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of corrosive ions found in power plant water and steam. , Chlorides and ... turbines and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions ...
(Date:3/28/2017)... ... 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics ... in the country to sit on the 2017 National Advisory Board for Allergan’s Facial ... Dr. Harper helped propel the clinic from a small start-up to number 78 in ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System ... procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. ...
(Date:3/28/2017)... ... 28, 2017 , ... With expansion and efficiency in mind, Patten Seed Company ... seed processing plant opened in Marshallville in 2006, and a bagging and shipping facility ... for transition of Patten Seed operations to the Middle Georgia location from their previous ...
Breaking Medicine News(10 mins):